Dr Stefano Schipani

  • Honorary Clinical Senior Lecturer (Institute of Cancer Sciences)

telephone: 01413017011
email: Stefano.Schipani@glasgow.ac.uk

Beatson Cancer Centre, Office 21 Level 4, 1053 Great Western Road, Glasgow, G12 0yn

Research interests

Radiotherapy plays a leading role in the treatment of head and neck cancer. Technical development and translational investigations can lead to better tumour control and reduced radiotherapy related complications.

Our research is focused on:

- Image Guided Radiotherapy (IGRT): integration of anatomical (CT, aMRI) and functional (PET, fMRI) imaging to better define the target volume and identify potentially radioresistant cancer sub-volumes.

- Tumour and normal tissue dosimetric predictive models: Volumetric Modulated Arc Therapy (VMAT) allows more accurate dose conformity on the target volume and better sparing of the organs at risk; new models are under investigation to predict tumour response and late radiotherapy related morbidity.

- New radiosensitizers: new agents administered concurrently with radiotherapy can enhance the tumour response; our group is leading a UK multicentric phase I study with a novel agent previously tested in animal models.

- Human Papillomavirus (HPV)-related models: HPV is a positive prognostic factor in head&neck cancer; stratification, personalisation and deintensification of treatment depending on HPV status will lead to better tumour control and less morbidity. 

- Adaptive radiotherapy: tumour and normal tissues change anatomically and functionally during radiotherapy; adapting radiotherapy during the course of treatment is a technical and resource consuming process; adaptive protocols are the next generation challenge.

Sponsored clinical trials 

“An Open, Phase I, Exploratory Study of MTL-005 Radiosensitization in Patients With Advanced Carcinoma of the Head and Neck: Part 1 to Evaluate Safety in a Dose Escalation Design in Patients Indicated for Palliative Radiotherapy, Part 2 to Evaluate Safety and Efficacy in a Dose-Escalation Design in Patients Indicated for Cisplatin Chemoradiotherapy"

Sponsor: MorEx Development Partners LLP



List by: Type | Date


Grants and Awards listed are those received whilst working with the University of Glasgow.

  • A pilot study to assess acute gastro-intestinal (GI) and genito-urinary (GU) toxicity in patients treated with flattening filter free (FFF) stereotactic ablative RT (SABR) for prostate cancer.
    Cancer Research UK
    2012 - 2013
  • The epidemiology of human papillomavirus associated oropharyngeal cancers in the west of Scotland
    Cancer Research UK
    2012 - 2013